As BMS Braces For Major LOEs, It All Comes Down To Execution
16 NMEs Expected By The End Of This Decade
As Bristol Myers Squibb works through the Revlimid loss of exclusivity and prepares for the Eliquis and Opdivo LOEs, execution is key as it refills its pipeline with new launches and acquired assets.
